Horizon broadens industry-leading gene editing capabilities through extension of key CRISPR license and grant-funded research

Horizon Discovery Group plc (LSE:HZD) (“Horizon” or the “Company”), the world leader in the application of gene editing technologies, today announces that it has broadened its gene editing capabilities through the amendment of a pre-existing license with ERS Genomics to include the full commercial rights for the use of CRISPR edited cell lines for the Good Manufacturing Practices (GMP) manufacturing of biotherapeutics. The Company has also entered into a grant-funded collaboration with Solentim, the developer of the Cell Metric^TM and dedicated instrumentation for cell line development, to establish automated approaches for the gene editing of cell lines.With this license amendment, Horizon now adds the right to use CRISPR edited cell lines in GMP biomanufacturing. This extends Horizon’s coverage for CRISPR to include virtually all non-therapeutic applications, strengthening its core capabilities and keeping the Company at the forefront of gene editing. Further, through the recently signed global agreement between key CRISPR IP holders (CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics), this license now includes consents from all the patent co-owners and thereby provides Horizon with worldwide freedom to operate with respect to this foundational intellectual property. Financial terms of the amendment were not disclosed.Horizon’s Bioproduction business has proven to be a strong source of growth since launch in December 2014, and now represents a large opportunity for the Company with access to a market estimated to be worth £3.0 billion in 2015¹. By offering cutting-edge biomanufacturing cell lines that are constantly improving through a process of continuous innovation to organisations of all sizes, through a disruptive open access business model based on one-time upfront payments from customers independent of the future success of the biotherapeutic, Horizon is well positioned to realise significant market success.  To date, Horizon has engaged with customers in 29 cell line evaluations, leading to a total of 10 licenses taken contributing over £1.75 million in revenues.  A further 16 cell line evaluations are currently underway, several of which are expected to conclude within Q1 2017.Horizon has also entered into a two-year collaboration with Solentim Ltd for the development of an automated manufacturing platform for the genome editing of mammalian cells. The project is being funded by Innovate UK, the UK’s-innovation-agency, under the Collaborative Research in Manufacturing and Materials scheme for a total of £764,300, of which Horizon will receive £523,000. The aim of this project is to establish new and innovative approaches for the manufacture of high-value, genome-edited, cell lines at a greater throughput and at a significantly reduced cost.  This will provide Horizon with the ability to rapidly expand its product offering while making these cells available to the market at a highly competitive price.
Dr. Darrin Disley, Chief Executive Officer, Horizon Discovery, commented:“Gene editing underpins Horizon’s operations, enabling us to be the go-to industry ‘Cell Builders’. Through the extension of our CRISPR license with ERS Genomics, we now have a deeper toolbox of gene editing options, which includes our exclusive rAAV technology, to apply to the generation of GMP biomanufacturing cell lines. Bioproduction was only a small part of Horizon’s portfolio at the time of our IPO, however the business has since outperformed expectations, becoming a significant source of growth and is an important part of our business plan going forward.“The efficient application of gene editing technologies is as important to our success as is access to them. Our grant-funded collaboration with Solentim has the potential to have a major impact on the rate and cost of cell line development for Horizon, further strengthening our competitive market position, and accelerating the move from customer-performed cell line development to a fully outsourced model, similar to what has occurred in the research antibody market.”
Mr. Eric Rhodes, Chief Executive Officer, ERS Genomics, said:“The rapid adoption of gene editing, led by CRISPR, is transforming all areas of life sciences.  We are pleased to be able to expand Horizon’s license for the use of CRISPR to include GMP biomanufacturing applications, as they are exceptionally well positioned to support the needs of biotherapeutic manufacturers around the world.”
About Horizon’s Biomanufacturing platform:
Biological therapeutics made up seven of the top ten best selling drugs of 2015², and they feature extensively in developmental pipelines.  However, access to bioproduction cell lines for their manufacture can be cost prohibitive and is often restricted in ways that prevent their further optimisation by customers. This stifles innovation and means that drugs are not always getting to market due to the inability to generate bioproduction cell lines that meet the needs of commercial release.Horizon is using its more than 10 years’ experience in the successful delivery of cell line engineering projects to improve biological therapeutics manufacturing. As well as developing a tool box of cell lines for the manufacture of a range of current and next generation biological therapeutics, Horizon aims to encourage innovation in other organisations by allowing access to its state of the art bioproduction cell line platform (CHO SOURCE) under flexible licensing terms that include allowing the further modification of cells.In most cases, cell line licenses are preceded by an evaluation period by the customer, each of which provides £10k to £30k in revenue and runs for 6-12 months.  Upon completion, if a commercial license is taken, each project is valued at between £150,000 and £350,000 dependent on terms.
About Horizon’s gene editing IP portfolio:
Horizon holds a  number  of  CRISPR-related  licenses,  including  a  worldwide commercial license to the UC Berkeley and Broad Institute family of CRISPR patents signed in 2014, and a  license  to  patents  filed  by  Harvard  University  based  on  discoveries  made  by  Dr. George  Church  and  colleagues  taken  in  June  2013.The Company continues  to  protect  its intellectual property through innovation, with key patents   pending including those relating  to  the  use  of  CRISPR  gene  editing  to  engineer  fully  haploid human  cells,  and a further patent pending  relating  to  a  high-throughput  approach  for using  CRISPR  to  modify virtually  any  genetically-defined cell line. In  addition  to  the  CRISPR  technology  licenses,  Horizon  has  an  exclusive  worldwide  license to use rAAV gene editing technology from the University of Washington, making Horizon the only company authorised to utilise this technology commercially. Horizon also has a worldwide exclusive license from Sigma-Aldrich for the use of ZFN technology in the engineering of in vivo disease models in mice, rats and rabbits.W. Downey, “Biopharmaceutical Contract Manufacturing Capacity Expansions”, Contract Pharma, June 2, 2015https://www.pharmacompass.com/radio-compass-blog/top-drugs-by-sales-revenue-in-2015-who-sold-the-biggest-blockbuster-drugsGlossary:Biomanufacturing: A type of manufacturing that utilises biological systems to produce commercially important biomaterials and biomolecules for use in medicinesBiotherapeutic: A therapeutic material produced using biological means, for example an antibodyCRISPR/Cas9: A gene editing technology that enables genomic modifications in a wide variety of organisms and tissues with high efficiencyrAAV: A gene editing technology, exclusive to Horizon for non-therapeutic applications, which allows cells to be edited with extreme precision and virtually no risk of unforeseen errors
For further information from Horizon Discovery Group plc, please contact:Horizon Discovery Group plc
Darrin Disley, Chief Executive Officer
Richard Vellacott, Chief Financial Officer
Chris Claxton, VP Investor Relations
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Joint Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
RBC Capital Markets (Joint Broker)
Paul Tomasic / Marcus Jackson
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Susan Stuart / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
Zyme Communications (Trade and Regional Media)
Katie Odgaard
Tel: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com
Tel: +44 (0) 20 7653 4000
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE:HZD) (“Horizon”), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.Horizon’s core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines.Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and animal models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon’s commercial offering has been adopted by c. 1,600 unique research organisations in over 50 countries as well as in the Company’s own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis.Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.